STING-associated vasculopathy with onset in infancy

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Jul 2023Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®

Case Comprehensive Cancer Center — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for STING-associated vasculopathy with onset in infancy.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

WEGOVY

(SEMAGLUTIDE)accelerated

Novo Nordisk

GLP-1 Receptor Agonist [EPC]

12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1N/A
1Total recruiting
Search clinical trials for STING-associated vasculopathy with onset in infancy

Recent News & Research

1 article
BREAKINGFDAMar 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Read ↗

Browse all STING-associated vasculopathy with onset in infancy news →

Specialist Network

No specialists currently listed for STING-associated vasculopathy with onset in infancy.

View all STING-associated vasculopathy with onset in infancy specialists →

Quick Actions